Potential therapies used in MIS-A include intravenous immunoglobulin (IVIg), aspirin, anticoagulation, corticosteroids and tocilizumab. 1 With our evolving understanding of K-MIS-A, treatment protocols are yet to be standardized. Although we gave only anticoagulants to our patient, he recovered completely without any cardiac sequelae, as seen at follow-up. The CDC's detailed data on 27 cases of MIS-A included two cases with deranged inflammatory markers, ECG and TTE changes, which recovered on only anticoagulants without IVIg or steroids. 1 Hence, there might be a subset of patients with K-MIS-A who may recover spontaneously without conventional therapies. The focus of our case is to reiterate the possibility of COVID-19-associated K-MIS-A and timely diagnosis through early identification of dermatological manifestations and antibody testing, even when COVID-19 RT-PCR is negative. Further information on the investigations is available on direct request.